The Immune Tolerance Network is an international clinical research consortium founded by the National Institutes of Health, whose mission is to accelerate the clinical development of immune tolerance therapies through a unique development model.
The ITN development model is a highly interactive process that capitalizes on our wide-ranging, multidisciplinary expertise, provided by an advisory board of highly respected faculty from institutions world-wide. It begins with the application process - from pre- and post-application support, to formal Q&A sessions with reviewers, we help investigators develop high quality research studies.
The ITN looks beyond the traditional clinical trial endpoints of safety and efficacy, actively investigating the mechanisms of tolerance induction and maintenance, integrating hypothesis-driven, mechanism-based research into all its clinical trials. In addition to clinical efficacy, the ITN is seeking to define new biomarkers of tolerance in human disease. Supported by an unprecedented array of core facilities offering state-of-the-art genetic, cellular and immunologic assays, the ITN is generating some of the first combined clinical and mechanistic data on immune tolerance induction in humans.
In the ITN's unique hybrid academic/industry model, academia, government and industry all play a vital role the conduct and planning of clinical studies. With a flexible partnership model, the ITN seeks to create a synergy between partners to help each meet their research goals.
 |
ITN Informational Brochure A brief introduction to the ITN for academic scientists and industry professionals. > Download [pdf - 172kB] |
|
 |
10 Short Stories of Success We're proud of our accomplishments at the ITN. This short booklet highlights just a few of them. > Download [pdf - 577kB] |
|
 |
2007 ITN Research Report An overview of ITN progress towards our tolerance mission. > Download [pdf - 1.6MB] |
